-
Compass Therapeutics NASDAQ:CMPX
Location: | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
81.8M
Cash
126.7M
Avg Qtr Burn
-11.21M
Short % of Float
5.51%
Insider Ownership
18.08%
Institutional Own.
70.96%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tovecimig (CTX-009) (DLL4 and VEGF-A bispecific antibody) Details Cancer, Biliary Tract Cancer | Phase 2/3 Data readout | |
CTX-009 (DLL4 and VEGF-A bispecific antibody) Details Cancer, Colorectal cancer | Phase 2 Initiation | |
CTX-471 +/- KEYTRUDA® (pembrolizumab) Details Cancer, Small cell lung cancer, Non-small cell lung carcinoma, Melanoma | Phase 2 Initiation | |
CTX-8371 (PD-1 x PD-L1) Details Cancer, Solid tumor/s | Phase 1 Data readout | |
CTX-10726 (PD-1 x VEGF-A bispecific antibody) Details Solid tumor/s | IND Submission |